Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Dysgeusia
Clinical narrative: COVID-19/Treatment of COVID-19; Metallic taste; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19/Treatment of COVID-19) and DYSGEUSIA (Metallic taste) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033F21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Jansen (Dose Number: 1 Batch/Lot No: 1805018) on 11-Mar-2021. Past adverse reactions to the above products included No adverse event with Jansen. Concurrent medical conditions included Allergy. Concomitant products included ETHINYLESTRADIOL, NORGESTIMATE (TRI-LO-SPRINTEC) and MENTHOL (ROBITUSSIN [MENTHOL]) for an unknown indication.    On 05-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-May-2022, the patient experienced COVID-19 (COVID-19/Treatment of COVID-19) and DYSGEUSIA (Metallic taste). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) on 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19/Treatment of COVID-19) and DYSGEUSIA (Metallic taste) outcome was unknown. Not Provided          Patient was taking any other medications or products within 2 weeks of starting COVID-19 treatment. Device Date was reported as 26-May-2022  Active Drug substance name for Robitussin was reported as Cough suppressant Active Drug substance name for Trilosprintec was reported as Birth control  Company comment:  This spontaneous case concerns a patient of unknown age and gender, with no reported relevant medical history, who experienced, unexpected, non-serious, of COVID-19, approximately 6 months after receiving mRNA-1273 vaccine as a second dose, along with non-serious event of Dysgeusia. Interchange of vaccine products is noted in this case since the patient reported receiving 1 dose of Janssen, approximately 8 months before receiving mRNA-1273 vaccine. The patient was started with Nirmatrelvir-Ritonavir (Paxlovid) dose, duration and frequency were unknown. Clinical course, treatment details and diagnostic tests are not available in this report. The outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a patient of unknown age and gender, with no reported relevant medical history, who experienced, unexpected, non-serious,  of COVID-19, approximately 6 months after receiving mRNA-1273 vaccine as a second dose, along with non-serious event of Dysgeusia. Interchange of vaccine products is noted in this case since the patient reported receiving 1 dose of Janssen, approximately 8 months before receiving mRNA-1273 vaccine. The patient was started with Nirmatrelvir-Ritonavir (Paxlovid) dose, duration and frequency were unknown. Clinical course, treatment details and diagnostic tests are not available in this report. The outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.